Patent · US Active

Combination therapy for the treatment of gastrointestinal stromal tumor

US11986463B2 · kind B2 · utility

0Cited by

96References

11Claims

0Family size

Assignee

Deciphera Pharmaceuticals, LLC · US

Inventors

Daniel L. Flynn · Lawrence, US
Bryan D. Smith · Madison, US
Anu Gupta · Waltham, US

Key dates

Filing date	Jul 30, 2020
Grant date	May 21, 2024
Priority date	—
Expiry date	Dec 17, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.